Samchundang Pharm held an IR meeting for individual shareholders on April 11, focusing on its three growth pillars shared during recent Hong Kong and Singapore NDRs. The company emphasized its transition from an Eylea biosimilar player to a platform-driven firm, but confirmed no additional undisclosed information would be released due to regulatory constraints.
Hong Kong NDR Highlights
During the NDRs on April 8-9, Samchundang presented three core growth axes beyond its Eylea biosimilar (SCD411): the oral conversion platform (S-PASS), subcutaneous injection formulation platform (SC Reform), and long-acting injectable (LAI). The S-PASS platform received the most attention, with the company detailing strategies for oral insulin, semaglutide, tirzepatide, and antibody drugs.
S-PASS Platform Progress
Samchundang recently obtained global Phase 1 clinical approval for oral insulin from Germany's BfArM and the EMA, positioning this as a key validation event. If successful, the platform could expand into GLP-1 obesity/diabetes treatments and antibody drugs. The company also plans a human pilot study for oral tirzepatide in Q4 2025, targeting the obesity market.
SC Reform and LAI Strategies
For SC Reform, Samchundang aims to convert IV-administered Keytruda and Opdivo into subcutaneous formulations, leveraging its rHuPH20 enzyme secured through a strategic partner. The company targets the $50 billion global SC biologics market, emphasizing cost competitiveness through proprietary purification and high-concentration technology, achieving double the yield and utilizing existing Eylea biosimilar production infrastructure.
What Buyers Should Watch
Overseas distributors and clinic buyers should monitor Samchundang's oral insulin clinical timeline and SC Reform partnership developments, though the company has indicated no further details will be disclosed publicly at this stage. The firm's ability to validate its platforms through regulatory approvals will be critical for future product availability and market entry strategies.
Regulatory and Channel Signals
Samchundang's cautious approach follows recent financial authority guidance on disclosure compliance. The company stated it will only discuss publicly available information during the IR, limiting responses on high-interest topics like oral insulin schedules and SC Reform partnerships. This suggests near-term transparency may be constrained, but the successful NDRs indicate strong investor engagement.
Source: Read the original report | Published: June 11, 2026